• Publications
  • Influence
Guidelines for the use and interpretation of assays for monitoring autophagy
These guidelines are presented for the selection and interpretation of methods for use by investigators who aim to examine macroautophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes. Expand
Revised international prognostic scoring system for myelodysplastic syndromes.
This revised IPSS-R comprehensively integrated the numerous known clinical features into a method analyzing MDS patient prognosis more precisely than the initial IPSS and should prove beneficial for predicting the clinical outcomes of untreated MDS patients and aiding design and analysis of clinical trials in this disease. Expand
Clinical effect of point mutations in myelodysplastic syndromes.
Mutations in TP53, EZH2, ETV6, RUNX1, and ASXL1 are predictors of poor overall survival in patients with myelodysplastic syndromes, independently of established risk factors. Expand
Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia.
Several genetic alterations that activate kinase signaling in Ph-like ALL induce transformation that is attenuated with tyrosine kinase inhibitors, suggesting the treatment outcome of these patients may be improved with targeted therapy. Expand
CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer.
The results support a new mechanism of MYC and WNT regulation by the novel lncRNA CCAT2 in colorectal cancer pathogenesis, and provide an alternative explanation of the SNP-conferred cancer risk. Expand
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.
Disease alleles that activate signal transduction are common in myeloid malignancies; however, there are additional unidentified mutations that contribute to myeloid transformation. Based on theExpand
New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge.
A new and comprehensive cytogenetic scoring system based on an international data collection of 2,902 patients with primary MDS and oligoblastic acute myeloid leukemia (AML) after MDS treated with supportive care only is proposed, providing clear prognostic classification in 91% of all patients. Expand
Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes.
Combining the LR-PSS and EZH2 mutation status identifies 29% of patients with lower-risk MDS with a worse-than-expected prognosis, and these patients may benefit from earlier initiation of disease-modifying therapy. Expand
Loss of the Tumor Suppressor BAP1 Causes Myeloid Transformation
Identifying BAP1 Targets Inactivating mutations in the deubiquitinating enzyme BAP1 have been associated with cancer. Dey et al. (p. 1541, published online 9 August; see the Perspective by White andExpand
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.
Overall, Tet2 loss appears to sensitize cells to treatment with AZA in vivo, and TET2 mutations can identify patients more likely to respond to HMAs. Expand